
Continuous low-dose glucocorticoid regimens are better than tapering for controlling disease activity in rheumatoid arthritis over a six-month period, show the results of the first double blind clinical trial to evaluate an oral glucocorticoid dose-tapering regimen with stable biological background therapy in rheumatoid arthritis.





























